AbelZeta announces publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced hepatocellular carcinoma
ROCKVILLE, Md. and SHANGHAI, July 23, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or "the Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced a...
Covered in this story
What has happened since
- Genuine Parts Company is up 4.8% since this was published, 89 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $GPC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Genuine Parts Company →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.